COLLPLANT HOLDI/S (NASDAQ: CLGN) is one of 27 public companies in the “Surgical appliances & supplies” industry, but how does it contrast to its peers? We will compare COLLPLANT HOLDI/S to similar businesses based on the strength of its earnings, dividends, analyst recommendations, valuation, risk, institutional ownership and profitability.
This is a summary of current ratings and price targets for COLLPLANT HOLDI/S and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|COLLPLANT HOLDI/S Competitors||175||823||1452||73||2.56|
Earnings & Valuation
This table compares COLLPLANT HOLDI/S and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|COLLPLANT HOLDI/S||$480,000.00||-$6.02 million||-2.49|
|COLLPLANT HOLDI/S Competitors||$1.39 billion||$210.14 million||21.35|
COLLPLANT HOLDI/S’s peers have higher revenue and earnings than COLLPLANT HOLDI/S. COLLPLANT HOLDI/S is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares COLLPLANT HOLDI/S and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|COLLPLANT HOLDI/S Competitors||-154.96%||-220.52%||-23.54%|
Institutional and Insider Ownership
58.0% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 10.3% of shares of all “Surgical appliances & supplies” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
COLLPLANT HOLDI/S peers beat COLLPLANT HOLDI/S on 8 of the 9 factors compared.
About COLLPLANT HOLDI/S
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.